Bionomics
Bionomics is a drug discovery and development company focused on new treatments for cancer and serious disorders of the central nervous system. Through application of its proprietary technology platforms, Bionomics has generated multiple drug candidates and targets in the therapeutic areas of Cancer, Anxiety, Multiple Sclerosis and Epilepsy.
Bionomics makes further gains with anti-anxiety drug compound BNC210
New data to be presented today by Bionomics (ASX: BNO) will show that its compound BNC210 exhibits an antidepressant effect - without symptoms of physical dependence.
This supports previous research that showed that BNC210 does not cause abuse liability or development of tolerance.
Antidepressants have been shown to increase the formation and development of nerve cells in various regions of the brain and to also induce nerve growth in culture.
Studies of the effects of BNC210 on nerve cells in culture have shown that it too enhances their growth, consistent with antidepressant activity.
BNC210 Project Leader Dr Sue O’Connor will give a poster presentation at the Australian Neuroscience Society Annual Conference (ANS 2010) at 12pm today at the Sydney Convention Centre.
The title of the poster presentation is “The anxiolytic compound BNC210 exhibits an antidepressant effect without symptoms of physical dependence”.
Dr Sue O’Connor commented “The new results provide further support for the evaluation of BNC210 in humans for the treatment of anxiety and provide strong evidence for the potential utility of BNC210 in the treatment of depression”.
Abrupt cessation of current antidepressant medication may produce symptoms of withdrawal, such as changes in body weight, food intake or body temperature. Such changes signify physical dependence to the drug.
Importantly, these changes were not associated with BNC210 treatment of rats over 14 days and subsequent cessation of treatment when monitored over an 18 day period.
The data presented expands the evidence of antidepressant activity of BNC210, a novel compound which also displays potent activity in several models of anxiety.
The global antidepressant market reached sales of almost US$11 billion in 2008.
Blockbuster drugs such as Cymbalta [US$2.7B], Effexor, which is also used for the treatment of generalized anxiety disorder [US$3.9B], and Lexapro [US$2.29B] are the primary drug treatments.
Hence commercial potential for A$102 million market-capped, BNO's BNC210 compound is significant.
Other Bionomics news
-
16/03/10 Bionomics to present at Ultimate Healthcare & Biotechnology Event, March 24
-
02/03/10 Bionomics makes strides with clinical trial of anxiety compound
-
25/02/10 Europe's Edison Investment Research values Bionomics at twice current valuation
-
27/01/10 Bionomics BNC105 renal cancer trial commences in USA with Hoosier Oncology Group
Investors interested in Bionomics recently viewed
-
Access Pharmaceuticals (OTCBB: .ACCP)
-
Alliance Pharma plc (AIM: APH)
-
Amphion Innovations (LON: AMP)
-
Asterand (LSE: ATD)
-
Biocompatibles (LSE: BII)
-
BioNeutral Group (OTCBB: .BONU)
-
Circadian Technologies Limited (ASX: .CIR)
-
CogState (ASX: .CGS)
-
Eco Animal Health Group Plc (AIM: EAH)
-
Epistem (AIM: EHP)
-
ImmuPharma PLC (AIM: IMM)
-
Lipoxen Plc (AIM: LPX)
-
Medical Australia Limited (ASX: MLA)
-
Oxford Nutrascience (AIM: ONG)
-
Renovo Group Plc (LSE: RNVO)
-
Rexahn Pharmaceuticals (AMEX: RNN)
-
Starpharma (ASX: .SPL)
-
Stirling Products Limited (ASX: .STI)










